Rani Therapeutics Holdings, INC Form 4 insider transactions

Rani Therapeutics director Jean-Luc Butel amended the exercise prices of several stock options on December 16, 2024.

Rani Therapeutics director, Dennis Ausiello, amended the exercise prices of his stock options on December 16, 2024, with no changes to expiration dates or vesting schedules.

Rani Therapeutics director Lisa Ann Rometty amended the exercise prices of her stock options on December 16, 2024.

Rani Therapeutics director Laureen DeBuono amended the exercise prices of her stock options on December 16, 2024, with no changes to expiration dates or vesting schedules.

Andrew Farquharson, a director at Rani Therapeutics, had the exercise price of his stock options amended from $2.84 to $4.11 per share.

A director of Rani Therapeutics Holdings, Inc. amended the exercise price of their stock options from $2.84 to $4.11 per share on December 16, 2024.

Rani Therapeutics director Maulik Nanavaty amended the exercise prices of several stock options on December 16, 2024.

Kate McKinley, Chief Business Officer of Rani Therapeutics, acquired 17,960 shares of Class A Common Stock in a recent open market transaction.

Rani Therapeutics CEO, Imran Talat, acquired 10,296 shares of Class A Common Stock on December 9, 2024.

South Cone Investments Limited Partnership reports the sale of Rani Therapeutics Holdings, Inc. shares in multiple transactions.

Director Mir A Imran reports acquisition of 50,000 stock options in Rani Therapeutics Holdings, Inc.

Director Andrew Farquharson reports the acquisition of stock options in Rani Therapeutics Holdings, Inc.

Director Maulik Nanavaty reports acquisition of 50,000 stock options in Rani Therapeutics Holdings, Inc.

Director Laureen DeBuono reports the acquisition of stock options for 50,000 shares of Rani Therapeutics Class A Common Stock.

Director Dennis Ausiello reports acquisition of 50,000 stock options in Rani Therapeutics Holdings, Inc.

Lisa Ann Rometty, a director of Rani Therapeutics Holdings, Inc., was granted options to purchase 50,000 shares of Class A Common Stock on May 29, 2024.

Director Jean Luc Butel reports acquisition of 50,000 stock options in Rani Therapeutics Holdings, Inc.

Kate McKinley, Chief Business Officer of Rani Therapeutics Holdings, Inc., acquired stock options for 323,500 shares of Class A Common Stock on March 21, 2024.

Mir Hashim, Chief Scientific Officer of Rani Therapeutics, was granted stock options for 323,500 shares of Class A Common Stock on March 21, 2024.

Eric Groen, General Counsel of Rani Therapeutics Holdings, Inc., reports the acquisition of stock options for 323,500 shares of Class A Common Stock on March 21, 2024.

Rani Therapeutics CEO Talat Imran reports the acquisition of 1,085,000 stock options with an exercise price of $3.60 on March 21, 2024.

Chief Financial Officer of Rani Therapeutics, Svai Sanford, reports acquisition of stock options.